Targeted miR-34a delivery with PD1 displayed bacterial outer membrane vesicles-coated zeolitic imidazolate framework nanoparticles for enhanced tumor therapy

Int J Biol Macromol. 2023 Aug 30:247:125692. doi: 10.1016/j.ijbiomac.2023.125692. Epub 2023 Jul 5.

Abstract

MicroRNA (miRNA) has been widely used as an effective gene drug for tumor therapy, but its chemical instability limited its therapeutic application in vivo. In this research, we fabricate an efficient miRNA nano-delivery system using zeolitic imidazolate framework-8 (ZIF-8) coated with bacterial outer membrane vesicles (OMVs), aimed for cancer treatment. The acid-sensitive ZIF-8 core enables this system to encapsulate miRNA and release them from lysosome quickly and efficiently in the target cells. The OMVs engineered to display programmed death receptor 1 (PD1) on the surface provides a specific tumor-targeting capability. Using a murine breast cancer model, we show that this system has high miRNA delivery efficiency and accurate tumor targeting. Moreover, the miR-34a payloads in carriers can further synergize with immune activation and checkpoint inhibition triggered by OMV-PD1 to enhance tumor therapeutic efficacy. Overall, this biomimetic nano-delivery platform provides a powerful tool for the intracellular delivery of miRNA and has great potential in RNA-based cancer therapeutic applications.

Keywords: Cancer therapy; OMV; PD1/PD-L1; ZIF-8; miRNA delivery.

MeSH terms

  • Animals
  • Bacterial Outer Membrane
  • Drug Carriers
  • Mice
  • MicroRNAs* / genetics
  • Nanoparticles*
  • Zeolites*

Substances

  • Zeolites
  • Drug Carriers
  • MicroRNAs